The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use. ##STR00001## Also disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of a menaquinol compound as disclosed above, or a mixture thereof, and a pharmaceutically acceptable excipient, wherein the composition is effective for the treatment of a condition associated with vitamin K selected from for the treatment of osteoporosis and arteriosclerosis.

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use. ##STR00001## Also disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of a menaquinol compound as disclosed above, or a mixture thereof, and a pharmaceutically acceptable excipient, wherein the composition is effective for the treatment of a condition associated with vitamin K selected from for the treatment of osteoporosis and arteriosclerosis.

A polycarbonate resin composition, a molded article, a polycarbonate resin, and an end-capping agent for polycarbonate resins are provided. The polycarbonate resin composition contains: a polycarbonate resin having a terminal structure represented by Formula (A) and having a viscosity average molecular weight from 110.sup.4 to 510.sup.4, and a stabilizer. In Formula (A), R.sup.1 is selected from the group consisting of a hydrogen atom, halogen atoms, linear alkyl groups having from 1 to 9 carbons, branched alkyl groups having from 3 to 9 carbons, linear alkenyl groups having from 2 to 9 carbons, branched alkenyl groups having from 3 to 9 carbons, and aryl groups having from 6 to 12 carbons; and R.sup.2 to R.sup.7 are each independently selected from the group consisting of a hydrogen atom, alkyl groups having from 1 to 9 carbons, and alkoxy groups having from 1 to 9 carbons.

##STR00001##

A polycarbonate resin composition, a molded article, a polycarbonate resin, and an end-capping agent for polycarbonate resins are provided. The polycarbonate resin composition contains: a polycarbonate resin having a terminal structure represented by Formula (A) and having a viscosity average molecular weight from 110.sup.4 to 510.sup.4, and a stabilizer. In Formula (A), R.sup.1 is selected from the group consisting of a hydrogen atom, halogen atoms, linear alkyl groups having from 1 to 9 carbons, branched alkyl groups having from 3 to 9 carbons, linear alkenyl groups having from 2 to 9 carbons, branched alkenyl groups having from 3 to 9 carbons, and aryl groups having from 6 to 12 carbons; and R.sup.2 to R.sup.7 are each independently selected from the group consisting of a hydrogen atom, alkyl groups having from 1 to 9 carbons, and alkoxy groups having from 1 to 9 carbons.

##STR00001##

Compounds and methods related to the prevention and treatment of diseases and conditions, some of which are facilitated by melanogenesis are disclosed. Specifically, the present subject matter includes a series of compounds and compositions and their use for anti-melanogenic and antioxidant activity. This subject matter also includes the treatment of skin disorder due to acne vulgaris and related inflammatory and post inflammatory hyperpigmentation. Methods for synthesizing contemplated compounds are also disclosed.

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.

##STR00001##

Disclosed are solid forms of menaquinol and processes for obtaining them by chemical or enzymatic reduction of menaquinone. Said solid forms possess high stability to oxidation which allows effective use of menaquinol in the most common formulations wherein vitamin K2 is used.

Disclosed are solid forms of menaquinol and processes for obtaining them by chemical or enzymatic reduction of menaquinone. Said solid forms possess high stability to oxidation which allows effective use of menaquinol in the most common formulations wherein vitamin K2 is used.

Disclosed are solid forms of menaquinol and processes for obtaining them by chemical or enzymatic reduction of menaquinone. Said solid forms possess high stability to oxidation which allows effective use of menaquinol in the most common formulations wherein vitamin K2 is used.

Provided is a method with which it is possible to produce a polyalkenylphenol compound having a narrow molecular weight distribution and low viscosity at high purity and high yield. A poly 2-alkenyl aromatic ether compound having two or more phenol skeletons is subjected to Claisen rearrangement in the presence of a phenol or naphthol compound.